deltatrials
Recruiting PHASE1/PHASE2 NCT06208410

A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors

A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors

Sponsor: Risen (Suzhou) Pharma Tech Co., Ltd.

Conditions Advanced Solid Tumors
Interventions Capecitabine Tablets Dalpiciclib Isetionate Tablets Fluzoparib Capsules Fulvestrant injection JS105 Paclitaxel for Injection (Albumin Bound) Pyrotinib Maleate Tablets Toripalimab Injection
Updated 5 times since 2024 Last updated: Jul 22, 2025 Started: Jan 11, 2024 Primary completion: Feb 26, 2027 Completion: Feb 26, 2027

This PHASE1/PHASE2 trial investigates Advanced Solid Tumors and is currently actively recruiting participants. Risen (Suzhou) Pharma Tech Co., Ltd. leads this study, which shows 5 recorded versions since 2024 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

5 versions recorded

  1. Aug 2025 — Present [monthly]

    Recruiting PHASE1/PHASE2

  2. Sep 2024 — Aug 2025 [monthly]

    Recruiting PHASE1/PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  4. Apr 2024 — Jul 2024 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

  5. Feb 2024 — Apr 2024 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Jan 2024

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Risen (Suzhou) Pharma Tech Co., Ltd.
Data source: Risen (Suzhou) Pharma Tech Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Zhengzhou, China